Drug Trial Radar · NCT00616161
A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function
Last checked: Nov 19, 2026Latest source record: Feb 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Aug 2006
Primary completion
Jul 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- sigma-tau i.f.r. S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- MDS Pharma Services
- First posted
- Feb 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the minimum effective dose of Istaroxime, in patients requiring hospitalization for deterioration of chronic heart failure and left ventricular systolic dysfunction. This goal will be reached by comparing the hemodynamic effect of three different doses of the drug versus placebo. Efficacy will be measured as a change in Pulmonary Capillary Wedge Pressure from pre-infusion to the last assessment at six hours intravenous infusion.Secondary objectives will be to evaluate safety, tolerability and efficacy on other main hemodynamic parameters, echocardiographic and echo-doppler measurements, plus preliminary pharmacokinetics of the drug.
Conditions
- Heart Failure
Interventions
IstaroximeDrug
0.5 microgram/kg/min IV for 6 hours
IstaroximeDrug
1.0 microgram/kg/min IV for 6 hours
IstaroximeDrug
1.5 microgram/kg/min IV for 6 hours
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the minimum effective dose of ISTAROXIME by comparing the hemodynamic effect of 3 different doses of the drug versus placebo. Efficacy will be measured as a change in PCWP from right heart catheterization.Time frame: 6 hours drug infusion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.